ACE and chronic kidney disease: The main evidence on BP targets in children with CKD derives from the Effect of Strict Blood Pressure Control and ACE inhibition on the Progression of CKD in Pediatric Patients (ESCAPE) trial [69], which randomised 385 children (aged 3–18) with CKD, all treated with ACEis, to either intensive BP control (target 24-h MAP below the 50th percentile) or standard BP control (MAP between the 50th and the 99th percentile), and added additional medications that did not block the RAAS.